Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
← catalyst calendarNCT06057402 · readout in 2,012 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
80estimated
Sites
33
Countries
Australia, Canada, China +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-03 | actual | When the study began enrolling |
| Primary completion | 2032-02-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-02-22 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Intervention
- Drug: Elranatamab — also filed as Elrexfio
Primary outcomes
what the primary-completion date above is the date OFIncidence of nonserious adverse events (AEs) leading to permanent discontinuation
measured A minimum of 90 days after the last dose of study drug
Incidence of serious adverse events (SAEs)
measured A minimum of 90 days after the last dose of study drug
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed